Natriuretic Peptides in Kawasaki Disease: the Myocardial Perspective

Making a diagnosis of Kawasaki disease with certainty may be challenging, especially since the recognition of cases with incomplete diagnostic criteria and its consequences. In order to build the diagnostic case in daily practice, clinicians rely on clinical criteria established over four decades ago, aided by non specific laboratory tests, and above all inspired by experience. We have recently studied the diagnostic value of N-terminal pro B-type natriuretic peptide to improve the diagnostic certainty of cases with complete or incomplete clinical criteria. Our working hypothesis was based on the fact that myocarditis is present in nearly all Kawasaki disease patients supported by histology data. In this paper, we review these facts and the myocardial perspective from the diagnostic and the mechanistic standpoints.

[1]  J. Kanegaye,et al.  Cardiovascular biomarkers in acute Kawasaki disease. , 2013, International journal of cardiology.

[2]  Kei Takahashi,et al.  Histopathological characteristics of myocarditis in acute‐phase Kawasaki disease , 2012, Histopathology.

[3]  N. Dahdah,et al.  Value of amino‐terminal pro B‐natriuretic peptide in diagnosing Kawasaki disease , 2012, Pediatrics international : official journal of the Japan Pediatric Society.

[4]  Yoshihiro Onouchi,et al.  Genetics of Kawasaki disease: what we know and don't know. , 2012, Circulation journal : official journal of the Japanese Circulation Society.

[5]  J. Newburger,et al.  Genetics insights into the pathogenesis of Kawasaki disease. , 2012, Circulation. Cardiovascular genetics.

[6]  R. Uehara,et al.  Coronary artery lesions of incomplete Kawasaki disease: a nationwide survey in Japan , 2012, European Journal of Pediatrics.

[7]  C. Spurney,et al.  Increased Incidence of Incomplete Kawasaki Disease at a Pediatric Hospital After Publication of the 2004 American Heart Association Guidelines , 2012, Pediatric Cardiology.

[8]  R. Uehara,et al.  Late Intravenous Immunoglobulin Treatment in Patients With Kawasaki Disease , 2012, Pediatrics.

[9]  M. Ishii,et al.  Corticosteroid Pulse Combination Therapy for Refractory Kawasaki Disease: A Randomized Trial , 2012, Pediatrics.

[10]  Hiroki Sato,et al.  Ulinastatin, a Urinary Trypsin Inhibitor, for the Initial Treatment of Patients With Kawasaki Disease: A Retrospective Study , 2011, Circulation.

[11]  J. Burns,et al.  Evolution of Laboratory Values in Patients With Kawasaki Disease , 2011, The Pediatric infectious disease journal.

[12]  T Tanaka,et al.  ITPKC and CASP3 polymorphisms and risks for IVIG unresponsiveness and coronary artery lesion formation in Kawasaki disease , 2011, The Pharmacogenomics Journal.

[13]  A. Hata,et al.  Cyclosporin A Treatment for Kawasaki Disease Refractory to Initial and Additional Intravenous Immunoglobulin , 2011, The Pediatric infectious disease journal.

[14]  S. Chun,et al.  Log-transformed plasma level of brain natriuretic peptide during the acute phase of Kawasaki disease is quantitatively associated with myocardial dysfunction , 2011, Korean journal of pediatrics.

[15]  Y. Hong,et al.  Parameters to Guide Retreatment After Initial Intravenous Immunoglobulin Therapy in Kawasaki Disease , 2011, Korean circulation journal.

[16]  T. Hasegawa,et al.  Syndrome of inappropriate anti‐diuretic hormone in Kawasaki disease , 2011, Pediatrics international : official journal of the Japan Pediatric Society.

[17]  S. Colan,et al.  Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. , 2011, The Journal of pediatrics.

[18]  T. Shimo,et al.  Prediction of the Risk of Coronary Arterial Lesions in Kawasaki Disease by Brain Natriuretic Peptide , 2011, Pediatric Cardiology.

[19]  K. Gauvreau,et al.  Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study. , 2011, The Journal of pediatrics.

[20]  N. Dahdah,et al.  Etanercept as adjunctive treatment for acute Kawasaki disease: study design and rationale. , 2011, American heart journal.

[21]  H. Sugiyama,et al.  The 30-Year Outcome for Patients After Myocardial Infarction Due to Coronary Artery Lesions Caused By Kawasaki Disease , 2011, Pediatric Cardiology.

[22]  S. Colan,et al.  Noncoronary cardiac abnormalities are associated with coronary artery dilation and with laboratory inflammatory markers in acute Kawasaki disease. , 2011, Journal of the American College of Cardiology.

[23]  Y. Hong,et al.  Hyponatremia and Syndrome of Inappropriate Antidiuretic Hormone Secretion in Kawasaki Disease , 2010, Korean circulation journal.

[24]  Y. Chiou,et al.  Urinary cytokines and renal Doppler study in Kawasaki disease. , 2010, The Journal of pediatrics.

[25]  R. Sundel,et al.  Atypical and incomplete Kawasaki disease. , 2009, Best practice & research. Clinical rheumatology.

[26]  N. Dahdah,et al.  Natriuretic Peptide as an Adjunctive Diagnostic Test in the Acute Phase of Kawasaki Disease , 2009, Pediatric Cardiology.

[27]  H. Kim,et al.  Clinical factors causing hyponatremia in patients with mucocutaneous lymph node syndrome , 2009 .

[28]  B. Pyun,et al.  Elevation of the index of left ventricular mass during the acute and subacute phase of Kawasaki disease, and its association with indexes of diastolic function , 2009, Cardiology in the Young.

[29]  C. Stephenson,et al.  Amino-terminal pro-B-type natriuretic peptide testing in neonatal and pediatric patients. , 2008, The American journal of cardiology.

[30]  Y. Chiou,et al.  Renal scarring sequelae in childhood Kawasaki disease , 2007, Pediatric Nephrology.

[31]  Jun-bao Du,et al.  [Change in plasma N-terminal pro-brain natriuretic peptide in children with Kawasaki disease and its value in clinical practice]. , 2006, Zhonghua er ke za zhi = Chinese journal of pediatrics.

[32]  A. Freeman,et al.  Kawasaki disease: summary of the American Heart Association guidelines. , 2006, American family physician.

[33]  Hyunju Lee,et al.  NT-pro BNP:A new diagnostic screening tool for Kawasaki disease , 2006 .

[34]  Toru Watanabe,et al.  Hyponatremia in Kawasaki disease , 2006, Pediatric Nephrology.

[35]  Y. Kawano,et al.  Four cases of Kawasaki syndrome complicated with myocarditis. , 2006, Circulation journal : official journal of the Japanese Circulation Society.

[36]  Yoshikazu Nakamura,et al.  Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition) , 2005, Pediatrics international : official journal of the Japan Pediatric Society.

[37]  Walter R Wilson,et al.  Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Statement for Health Professionals From the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association , 2004, Circulation.

[38]  J. Takaya,et al.  A case of Kawasaki Disease associated with syndrome of inappropriate secretion of antidiuretic hormone , 2004, Acta paediatrica.

[39]  J. Bartunek,et al.  Brain and other natriuretic peptides: molecular aspects , 2004, European journal of heart failure.

[40]  M. Drazner,et al.  B-type natriuretic peptide in cardiovascular disease , 2003, The Lancet.

[41]  S. Shulman,et al.  Circulating Cardiac Troponin I Levels in Kawasaki Disease , 2001, Pediatric Cardiology.

[42]  Y. Kuramochi,et al.  Hemodynamic factors of thrombus formation in coronary aneurysms associated with Kawasaki disease , 2000, Pediatrics international : official journal of the Japan Pediatric Society.

[43]  H. Kawaguchi,et al.  Plasma brain natriuretic peptide concentrations in patients with Kawasaki disease , 2000, Pediatrics international : official journal of the Japan Pediatric Society.

[44]  S. Colan,et al.  Abnormal myocardial mechanics in Kawasaki disease: Rapid response to γ-globulin , 2000 .

[45]  M. Ghazizadeh,et al.  Ultrastructural characteristics of myocardial and coronary microvascular lesions in Kawasaki disease. , 1999, Microvascular research.

[46]  K. Kim,et al.  Elevation of Cardiac Troponin I in the Acute Stage of Kawasaki Disease , 1999, Pediatric Cardiology.

[47]  T. Ichiyama,et al.  Cerebral hypoperfusion during acute Kawasaki disease. , 1998, Stroke.

[48]  K. Kim,et al.  Changes in cardiac troponin I in Kawasaki disease before and after treatment with intravenous gammaglobulin. , 1998, Japanese circulation journal.

[49]  H. Pomerance,et al.  Nelson Textbook of Pediatrics. , 1997, Archives of pediatrics & adolescent medicine.

[50]  C. Kao,et al.  Labeled WBC Cardiac Imaging and Two‐Dimensional Echocardiography to Evaluate High‐Dose Gamma Globulin Treatment in Kawasaki Disease , 1995, Clinical nuclear medicine.

[51]  K. Nakao,et al.  Molecular biology and biochemistry of the natriuretic peptide system. II: Natriuretic peptide receptors. , 1992, Journal of hypertension.

[52]  H. Yanagawa,et al.  Mortality among children with Kawasaki disease in Japan. , 1992, The New England journal of medicine.

[53]  T. Nakada,et al.  Histopathological study on Kawasaki disease with special reference to the relation between the myocardial sequelae and regional wall motion abnormalities of the left ventricle. , 1992, Japanese circulation journal.

[54]  C. Kao,et al.  Tc‐99m HMPAO Labeled WBC Scan for the Detection of Myocarditis in Different Phases of Kawasaki Disease , 1992, Clinical nuclear medicine.

[55]  M Takahashi,et al.  A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. , 1991, The New England journal of medicine.

[56]  M. Takahashi.  Myocarditis in Kawasaki syndrome. A minor villain? , 1989, Circulation.

[57]  S. Colan,et al.  Left ventricular contractility and function in Kawasaki syndrome. Effect of intravenous gamma-globulin. , 1989, Circulation.

[58]  M. Takano,et al.  Gallium-67 myocardial imaging for the detection of myocarditis in the acute phase of Kawasaki disease (mucocutaneous lymph node syndrome): the usefulness of single photon emission computed tomography. , 1987, British heart journal.

[59]  H. Kato,et al.  Myocardial infarction in Kawasaki disease: clinical analyses in 195 cases. , 1986, The Journal of pediatrics.

[60]  H. Nakano,et al.  HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN FOR KAWASAKI DISEASE , 1983, The Lancet.

[61]  T. Kamiya,et al.  Cardiac biopsy in Kawasaki disease , 1981, Heart and Vessels.

[62]  Y. Hamashima,et al.  General Pathology Of Kawasaki Disease , 1980, Acta pathologica japonica.

[63]  T. Kawasaki,et al.  KAWASAKI DISEASE: A WORLDWIDE SURVEY , 1979, The Lancet.

[64]  Y. Hamashima,et al.  Pathology of the heart in Kawasaki disease. , 1978, Pediatrics.

[65]  C. Debenedetti,et al.  Mucocutaneous lymph node syndrome in Arizona. , 1976, American journal of diseases of children.

[66]  T. Kawasaki,et al.  [Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children]. , 1967, Arerugi = [Allergy].

[67]  Hal B. Jenson,et al.  Nelson Textbook of Pediatrics , 1965 .

[68]  M. Marshall.  STERILISATION BY STEAM UNDER INCREASED PRESSURE; A THIRD COMMUNICATION TO THE MEDICAL RESEARCH COUNCIL BY THE WORKING PARTY ON PRESSURE-STEAM STERILISERS. , 1964, Lancet.

[69]  D. Tayloe,et al.  Pediatrics , 1927, The Indian Medical Gazette.

[70]  岸本 慎太郎.  Increased plasma type B natriuretic peptide in the acute phase of Kawasaki disease , 2012 .

[71]  J. Graham.  Kawasaki Disease at the Extremes of the Age Spectrum , 2010 .

[72]  N. Dahdah,et al.  Follow-Up Chest X-Ray in Patients with Kawasaki Disease: The Significance and Clinical Application of Coronary Artery Macro-Calcification , 2009, Pediatric Cardiology.

[73]  M. Rauh,et al.  NT-Pro-B-type Natriuretic Peptide in Infants and Children: Reference Values Based on Combined Data from Four Studies , 2008, Pediatric Cardiology.

[74]  W. Tang.  B-type natriuretic peptide: a critical review. , 2007, Congestive heart failure.

[75]  T. Mir,et al.  N-Terminal pro-brain natriuretic peptide: normal ranges in the pediatric population including method comparison and interlaboratory variability , 2006, Clinical chemistry and laboratory medicine.

[76]  T. Kamiya,et al.  Incidence of Stenotic Lesions Predicted by Acute Phase Changes in Coronary Arterial Diameter During Kawasaki Disease , 2004, Pediatric Cardiology.

[77]  L. Moreland,et al.  Mucocutaneous lymph node syndrome , 2004 .

[78]  S. Colan,et al.  Abnormal myocardial mechanics in Kawasaki disease: rapid response to gamma-globulin. , 2000, American heart journal.

[79]  K. Nakao,et al.  Molecular biology and biochemistry of the natriuretic peptide system , 1996 .

[80]  H. Nakano,et al.  Intravenous gamma-globulin for Kawasaki disease. , 1991, Acta paediatrica Japonica : Overseas edition.

[81]  N. Lightfoot,et al.  The descriptive epidemiology of Kawasaki syndrome in Canada, 1979-1985. , 1987, Progress in clinical and biological research.